Antiplatelet and antithrombin therapy
Copyright policy )Antiplatelet and antithrombin therapy
The contemporary pharmacologic treatment of acute myocardial infarction (AMI) includes reperfusion via a thrombolytic agent as well as adjunctive therapy with aspirin and heparin (1). Despite the advances made, current management is limited by the fact that infarct-related artery patency is achieved in only 60–80% of patients at 90 min and Thrombolysis in Myocardial Infarction (TIMI) grade 3 flow is achieved in only 30–55% of patients (2). Moreover, even after successful thrombolysis, reocclusion occurs in 5–10% of patients and is associated with increased morbidity and mortality (2, 3).
- Harvard University United States
- Massachusetts General Hospital United States
Aspirin, Heparin, Myocardial Infarction, Fibrinolytic Agents, Tissue Plasminogen Activator, Humans, Drug Therapy, Combination, Streptokinase, Thrombolytic Therapy, Platelet Aggregation Inhibitors, Randomized Controlled Trials as Topic
Aspirin, Heparin, Myocardial Infarction, Fibrinolytic Agents, Tissue Plasminogen Activator, Humans, Drug Therapy, Combination, Streptokinase, Thrombolytic Therapy, Platelet Aggregation Inhibitors, Randomized Controlled Trials as Topic
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).5 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!